Worth reading
36Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
35800
Shares (decrease in the number of underlying shares)Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of share acquisition rights as stock options (Nojima Co., Ltd. 24th Series of Share Acquisition Rights)
Who receives how much
Directors and other officers: 1,728,000 shares; employees: 9,642,700 shares; total: 11,370,700 shares (100 shares of the Company's common stock per share acquisition right)
Directors and other officers: 15 directors of the Company, 5 executive officers of the Company, 28 directors of the Company's subsidiaries, 5 corporate auditors of the Company's subsidiaries, and 26 executive officers of the Company's subsidiaries (79 people in total). Employees: 1,491 employees of the Company (9,? no breakdown by number of shares), and 3,275 employees of the Company's subsidiaries (4,766 people in total)
The lower thin line represents the existing number of shares to which these shares will be added.
Issue price of the share acquisition rights: nil. The exercise price is scheduled to be determined on 5 October 2026 and is currently undetermined.
Total issue value
Issue price of the share acquisition rights: not stated (no cash payment is required in exchange for the share acquisition rights). The total issue price of the shares to be issued upon exercise is undetermined.
Amount of funds to be raised
Not disclosed
発行済株式総数
The shares to be delivered upon exercise of these share acquisition rights are scheduled to be funded with treasury shares held by the Company, so no dilution will occur.
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Undetermined per share acquisition right (undetermined per share). Scheduled to be determined on 5 October 2026. No adjustment provision stated.
Exercise period
From 16 September 2029 to 15 September 2031
Number of Stock Acquisition Rights
Total issuance: 113,707 share acquisition rights. Outstanding unexercised share acquisition rights: Not disclosed
Reason for acquisition without consideration
Stated to be unchanged, but specific details are Not disclosed
Categories and Number of Persons Covered
15 directors of the Company, 5 executive officers of the Company, 28 directors of the Company's subsidiaries, 5 corporate auditors of the Company's subsidiaries, 26 executive officers of the Company's subsidiaries, 1,491 employees of the Company, and 3,275 employees of the Company's subsidiaries
Basis for determining the amount to be paid
The exercise price will be the closing price of the Company's common stock in regular trading on the Tokyo Stock Exchange on 5 October 2026, or, if no trade is concluded on that date, the closing price on the most recent preceding trading day.
Procedures under the Corporate Code of Conduct
Part of the grant is based on the delegated resolution of the 64th Annual General Meeting of Shareholders held on 19 June 2026. The grant to employees is based on a resolution of the Board of Directors under Article 238, Paragraph 1 and Article 240, Paragraph 1 of the Companies Act. The allotment date was changed to correct the deficiency in the period for notice to shareholders or public notice under Article 240, Paragraph 2 of the Companies Act.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of share acquisition rights as stock options (Nojima Co., Ltd. 24th Series of Share Acquisition Rights) |
| Number of shares to be issued or disposed of | Directors and other officers: 1,728,000 shares; employees: 9,642,700 shares; total: 11,370,700 shares (100 shares of the Company's common stock per share acquisition right) |
| Issue price and disposal price | Issue price of the share acquisition rights: nil. The exercise price is scheduled to be determined on 5 October 2026 and is currently undetermined. |
| Total issue value | Issue price of the share acquisition rights: not stated (no cash payment is required in exchange for the share acquisition rights). The total issue price of the shares to be issued upon exercise is undetermined. |
| Amount of funds to be raised | Not disclosed |
| Intended allottee | Directors and other officers: 15 directors of the Company, 5 executive officers of the Company, 28 directors of the Company's subsidiaries, 5 corporate auditors of the Company's subsidiaries, and 26 executive officers of the Company's subsidiaries (79 people in total). Employees: 1,491 employees of the Company (9,? no breakdown by number of shares), and 3,275 employees of the Company's subsidiaries (4,766 people in total) |
| Dilution Rate | The shares to be delivered upon exercise of these share acquisition rights are scheduled to be funded with treasury shares held by the Company, so no dilution will occur. |
| Basis for determining the amount to be paid | The exercise price will be the closing price of the Company's common stock in regular trading on the Tokyo Stock Exchange on 5 October 2026, or, if no trade is concluded on that date, the closing price on the most recent preceding trading day. |
| Exercise price | Undetermined per share acquisition right (undetermined per share). Scheduled to be determined on 5 October 2026. No adjustment provision stated. |
| Exercise period | From 16 September 2029 to 15 September 2031 |
| Number of Stock Acquisition Rights | Total issuance: 113,707 share acquisition rights. Outstanding unexercised share acquisition rights: Not disclosed |
| Reason for acquisition without consideration | Stated to be unchanged, but specific details are Not disclosed |
| Categories and Number of Persons Covered | 15 directors of the Company, 5 executive officers of the Company, 28 directors of the Company's subsidiaries, 5 corporate auditors of the Company's subsidiaries, 26 executive officers of the Company's subsidiaries, 1,491 employees of the Company, and 3,275 employees of the Company's subsidiaries |
| Procedures under the Corporate Code of Conduct | Part of the grant is based on the delegated resolution of the 64th Annual General Meeting of Shareholders held on 19 June 2026. The grant to employees is based on a resolution of the Board of Directors under Article 238, Paragraph 1 and Article 240, Paragraph 1 of the Companies Act. The allotment date was changed to correct the deficiency in the period for notice to shareholders or public notice under Article 240, Paragraph 2 of the Companies Act. |
Items this document does not state (14)
Estimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyTotal number of issued sharesTransfer restriction periodConditions for lifting transfer restrictionsTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Companies Act procedures requiring notice to shareholders or a public notice by 2 weeks before the allotment date had not been completed for grants to employees and subsidiary employees. In addition, if the allotment date differs for each grantee, the exercise price and exercise period will also differ, hindering the operation and administration of the scheme. The decrease in the number of grants to employees reflects changes among eligible grantees due to resignations and other factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.